

1 **SARS-CoV-2, SARS-CoV-1 and MERS-CoV viral load dynamics, duration of viral shedding**
2 **and infectiousness – a living systematic review and meta-analysis**

3

4 **Author:** Muge Cevik^{1,2}, Matthew Tate³, Ollie Lloyd^{2,4}, Alberto Enrico Maraolo⁵, Jenna
5 Schafers², Antonia Ho⁶

6

7 **Affiliations:**

8 1. Division of Infection and Global Health Research, School of Medicine, University of St
9 Andrews, UK

10 2. NHS Lothian Infection Service, Regional Infectious Diseases Unit, Western General
11 Hospital, Edinburgh, U.K.

12 3. Respiratory Medicine, University Hospital Wishaw, Wishaw, UK

13 4. Edinburgh Medical School, College of Medicine & Veterinary Medicine, University of
14 Edinburgh, UK

15 5. First Division of Infectious Diseases, Cotugno Hospital, AORN dei Colli, Naples, Italy.

16 6. MRC-University of Glasgow Centre for Virus Research, University of Glasgow, Glasgow,
17 UK

18

19 **Corresponding author:**

20 Dr Muge Cevik

21 Division of Infection and Global Health Research,

22 School of Medicine, University of St Andrews, Fife, KY16 9TF

23 Telephone number: +447732800814

24 Email address: mc349@st-andrews.ac.uk

25

26 **Keywords:** SARS-CoV-2, COVID-19, SARS-CoV-1, MERS-CoV, viral shedding, viral dynamics,

27 **infectiousness**

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 **ABSTRACT**

29 **Background:** Viral load kinetics and the duration of viral shedding are important determinants
30 for disease transmission. We aim i) to characterize viral load dynamics, duration of viral RNA,
31 and viable virus shedding of SARS-CoV-2 in various body fluids and ii) to compare SARS-CoV-2
32 viral dynamics with SARS-CoV-1 and MERS-CoV.

33 **Methods:** Medline, EMBASE, Europe PMC, preprint servers and grey literature were searched
34 to retrieve all articles reporting viral dynamics and duration of SARS-CoV-2, SARS-CoV-1 and
35 MERS-CoV shedding. We excluded case reports and case series with < 5 patients, or studies
36 that did not report shedding duration from symptom onset. PROSPERO registration:
37 CRD42020181914.

38 **Findings:** Seventy-nine studies on SARS-CoV-2, 8 on SARS-CoV-1, and 11 on MERS-CoV
39 were included. Mean SARS-CoV-2 RNA shedding duration in upper respiratory tract, lower
40 respiratory tract, stool and serum were 17.0, 14.6, 17.2 and 16.6 days, respectively. Maximum
41 duration of SARS-CoV-2 RNA shedding reported in URT, LRT, stool and serum were 83, 59, 35
42 and 60 days, respectively. Pooled mean duration of SARS-CoV-2 RNA shedding was positively
43 associated with age ($p=0.002$), but not gender ($p = 0.277$). No study to date has cultured live
44 virus beyond day nine of illness despite persistently high viral loads. SARS-CoV-2 viral load in
45 the upper respiratory tract appears to peak in the first week of illness, while SARS-CoV-1 and
46 MERS-CoV peak later.

47 **Conclusion:** Although SARS-CoV-2 RNA shedding in respiratory and stool can be prolonged,
48 duration of viable virus is relatively short-lived. Thus, detection of viral RNA cannot be used to
49 infer infectiousness. High SARS-CoV-2 titers are detectable in the first week of illness with an
50 early peak observed at symptom onset to day 5 of illness. This review underscores the
51 importance of early case finding and isolation, as well as public education on the spectrum of
52 illness. However, given potential delays in the isolation of patients, effective containment of
53 SARS-CoV-2 may be challenging even with an early detection and isolation strategy.

54 **Funding:** No funding was received.

55 INTRODUCTION

56 Viral load kinetics and the duration of viral shedding are important determinants for disease
57 transmission. They determine the duration of infectiousness which is a critical parameter to inform
58 effective control measures and disease modelling. While a number of studies have evaluated
59 SARS-CoV-2 shedding, viral load dynamics and duration of viral shedding reported across studies
60 so far have been heterogenous.¹ In several case series with serial respiratory sampling, peak viral
61 load was observed just before, or at the time of symptom onset.²⁻⁴ Viral ribonucleic acid (RNA)
62 shedding was reported to be persistent in the upper respiratory tract and in feces, for over one
63 month after illness onset.¹ However, the duration of SARS-CoV-2 RNA detection has not been well
64 characterized. A comprehensive understanding of viral load dynamics, length of viral shedding,
65 and how these relate to other factors, such as age and disease severity is lacking.

66 The aim of this systematic review and meta-analysis was to i) characterize the viral load dynamics
67 of SARS-CoV-2, duration of viral RNA shedding by reverse transcriptase polymerase chain
68 reaction (RT-PCR) and viable virus shedding in various body fluids and ii) compare SARS-CoV-2
69 viral dynamics with that of SARS-CoV-1 and MERS-CoV.

70 METHODS

71 *Search Strategy*

72 We retrieved all articles reporting viral dynamics and/or the duration of shedding of SARS-CoV-2,
73 SARS-CoV-1 or MERS-CoV in various specimens through systematic searches of major
74 databases including Medline, EMBASE, Europe PMC, pre-print databases (MedRxiv, BioRxiv) and
75 the grey literature from 1 January 2003 to 6th June 2020 using Medical Subject Headings (MeSH)
76 terms (Supplementary Material). We also manually screened the references of included original
77 studies to obtain additional studies. Studies prior to 2003 were excluded since the first recognized
78 case of SARS-CoV-1 was identified in March 2003.

79 This systematic review was registered in PROSPERO on 29th April 2020 (CRD42020181914) and
80 will be updated in three monthly intervals as a living systematic review.

81 *Study Selection*

82 Studies were eligible if they met the following inclusion criteria: (1) report on SARS-CoV-2, SARS-
83 CoV-1 or MERS-CoV infection and (2) report viral load kinetics, duration of viral shedding or viable
84 virus. We excluded: (1) review papers; (2) animal studies; (3) studies on environmental sampling;
85 (4) case reports and case series with < 5 participants, due to likely reporting bias; (5) papers where
86 the starting point of viral shedding was not clear or reported from post-discharge and (6) modelling
87 studies with no original data.

88 ***Data Extraction***

89 Two authors (MT and OL) screened and retrieved articles according to the eligibility criteria. Four
90 reviewers (MT, OL, JS, MC) performed full text review and final article selection. From each study,
91 the following variables were extracted as a minimum: name of first author, year of publication, city
92 and country, sample size, median age, sex ratio, time from symptom onset to viral clearance
93 detected by RT-PCR and culture in different specimens, and longest reported time to viral
94 clearance. If these data were not reported, we also contacted the authors to request the data. If
95 available, we extracted data on peak viral load, clinical outcome, and reported factors associated
96 with duration of viral shedding.

97 ***Risk of bias in included studies***

98 Two authors (OL and JS) independently assessed study quality and risk of bias using the Joanna
99 Briggs Institute (JBI) Critical Appraisal Checklist tools,⁵ which comprise standardized checklists,
100 for the different study designs included in this review. Any disagreements regarding grading of
101 quality were resolved through discussion with a third author (MC).

102 ***Meta-Analysis***

103 For every study included, mean duration of viral shedding and 95% confidence interval (CI) were
104 calculated. The random-effects model (DerSimonian or Laird) was applied to estimate a pooled
105 effect size. Forest plots illustrated the detailed representation of all studies based on the effect size
106 and 95% CI. If not reported, means and standard deviations were derived from sample size,
107 median, interquartile range (IQR), minimum and maximum values.⁶ Heterogeneity between studies
108 were quantified by the I^2 index and Cochran's Q test. Publication bias was not assessed as usual

109 appraisal methods are uninformative when meta-analysed studies do not include a test of
110 significance. A weighted meta-regression using an unrestricted maximum likelihood model was
111 performed to assess the impact of potential moderators on the pooled effect size (P-values <0.05
112 were considered significant). All statistical analyses were performed using Comprehensive Meta-
113 Analysis (CMA) version 3 software (Biostat, Englewood, mNJ).

114 **RESULTS**

115 The systematic search identified 1486 potentially relevant articles. Three hundred and fifty articles
116 were retrieved for full text review. After reviewing the eligibility criteria, a total of 79 studies on
117 SARS-CoV-2, eight on SARS-CoV-1, and 11 on MERS-CoV were included (Figure 1).

118 **Summary of SARS-CoV-2 studies**

119 Of the 79 papers included, 58 studies were conducted in China (Table 1). Six studies included
120 outpatient or community cases, the remainder comprised hospitalized patients only. Six studies
121 reported viral load dynamics exclusively in children.⁷⁻¹² Two additional studies included children,
122 but data on viral load dynamics were presented in aggregate with adults.^{13,14} One study reported
123 findings in renal transplant patients.¹⁵

124 **Median duration of viral shedding**

125 In total, 61 studies reported median or maximum viral RNA shedding in at least one body fluid
126 and six studies provided duration of shedding stratified by illness severity only. Of those, 43
127 (3229 individuals) reported duration of shedding in upper respiratory tract (URT), seven (260
128 individuals) in lower respiratory tract (LRT), 13 (586 individuals) in stool, and 2 studies (108
129 individuals) in serum samples were eligible for quantitative analysis. Means viral shedding
130 durations were 17.0 days (95% CI, 15.5-18.6), 14.6 days (95% CI, 9.3-20.0), 17.2 days (95% CI,
131 14.4-20.1) and 16.6 days (95% CI, 3.6-29.7), respectively (Figures 2 to 5). Maximum duration of
132 RNA shedding reported in URT, LRT, stool and serum were 83, 59, 35 and 60 days,
133 respectively.

134 Studies reporting duration of viral shedding in URT and stool samples were eligible for meta-
135 regression analysis. Pooled mean viral shedding duration was positively associated with age
136 (slope: +0.304; 95% CI, +0.115 to +0.493; $p = 0.002$ Fig 6), but not gender ($p = 0.277$,
137 Supplementary Fig 3). When adjusted for the proportion of male subjects in a multivariable
138 analysis, mean age was positively associated with the mean duration of viral shedding in URT
139 specimens ($p = 0.003$). There was a positive but non-significant association between mean age
140 and duration of shedding in stool ($p = 0.37$) (Supplementary Figure 4).

141 **Peak viral load**

142 The majority of studies evaluating SARS-CoV-2 viral load in serial URT samples demonstrated
143 peak viral loads within the first week of symptom onset.^{2,4,8,16-24} The highest viral loads were
144 reported either soon after or at the time of symptom onset^{2,8,16,23,24} or at day 3-5 of illness^{4,18,20,22}
145 followed by a consistent decline.

146 Five studies that evaluated viral load dynamics in LRT samples observed a peak viral load in the
147 second week of illness.^{4,18,20,23,25} In contrast, the dynamics of SARS-CoV-2 shedding in stool is
148 more erratic, with highest viral loads reported on day 7,¹⁸ 2-3 weeks,^{24,25} and up to 5-6 weeks
149 after symptom onset.²³ While several studies reported significantly higher viral titres in stool
150 compared to respiratory samples,^{8,25} Huang *et al.* reported lower viral load in stool than in both
151 LRT and URT samples early in the disease course.²³

152

153 **Severity and association with duration of viral shedding**

154 In total, 20 studies evaluated duration of viral RNA shedding based on disease severity. The
155 majority ($n=13$) reported longer duration of viral shedding in patients with severe illness than
156 those with non-severe illness,^{18,25-36} while five studies reported similar shedding durations
157 according to disease severity in URT samples^{17,19,37-39} and one study in stool samples.⁴⁰ Only
158 one study reported shorter viral shedding in moderate to severe illness compared to mild to
159 moderate illness.⁴¹ Six studies have performed comparative analysis based on severity of
160 illness,^{18,25,27,28,38,39} the majority ($n=5$) demonstrated significantly longer duration of shedding

161 among the severe illness group compared to the non-severe patients and only one study
162 observed no difference.³⁹ (Table 2).

163 **Other factors associated with prolonged shedding**

164 All but one study⁴² (n=10) that examined the impact of age on SARS-CoV-2 shedding identified
165 an association between older age and prolonged viral RNA shedding.^{25,26,28,33,37-39,43-45} Three
166 studies identified age as an independent risk factor for delayed viral clearance.^{25,26,38} Male sex
167 was also associated with prolonged shedding,^{25,38,46} and the association remained significant
168 even when patients were stratified based on illness severity.^{25,38} Corticosteroid treatment was
169 associated with delayed viral clearance in four studies,^{33,38,47,48} and one study that recruited 120
170 critically ill patients, found no difference between corticosteroid and control groups.⁴⁹

171 In a phase 2 open-label study evaluating interferon beta-1b, lopinavir–ritonavir, and ribavirin a
172 shorter duration of viral shedding was seen with combination treatment compared to the
173 control.⁵⁰ None of the antiviral regimens (chloroquine, oseltamivir, arbidol, and lopinavir/ritonavir)
174 independently improved viral RNA clearance.^{28,51} In a retrospective study of 284 patients,
175 lopinavir/ritonavir use was associated with delayed viral clearance even after adjusting for
176 confounders.²⁸

177 **Asymptomatic SARS-CoV-2 shedding**

178 Twelve studies reported on viral load dynamics and/or duration of viral shedding among patients
179 with asymptomatic SARS-CoV-2 infection (Table 3); two demonstrated lower viral loads among
180 asymptomatic patients compared to symptomatic patients,^{8,52} while four studies found similar
181 initial viral loads.^{13,14,53,54} However, Chau *et al* reported significantly lower viral load in
182 asymptomatic patients during the follow up compared to symptomatic patients.⁵³ Faster viral
183 clearance was observed in asymptomatic individuals in five out of six studies.^{13,28,53,55,56} The
184 exception Yongchen *et al.*, found longer shedding duration among asymptomatic cases, but the
185 difference was not significant.³⁶

186 **Live virus detection**

187 We identified 11 studies that attempted to isolate live virus. All eight studies that attempted virus
188 isolation in respiratory samples successfully cultured viable virus within the first week of illness,
189 ^{9,17,20,54,57-60} No live virus was isolated from any respiratory samples taken after day 8 of symptoms
190 in three studies,^{20,57,58} or beyond day 9 in two studies^{17,54} despite persistently high viral RNA loads.
191 One study demonstrated the highest probability of positive culture on day 3 of symptoms.⁵⁷ Arons
192 *et al.* cultured viable virus 6 days before typical symptom onset, however onset of symptom was
193 unclear.⁵⁴

194 The success of viral isolation correlated with viral load quantified by RT-PCR. No successful viral
195 culture was obtained from samples with a viral load below 10^6 copies/ml, ²⁰ Ct values >24 ,⁵⁷
196 or >34 ,^{54,58} with culture positivity declining with increasing Ct values.⁵⁸ Several other studies
197 cultured live virus from RT-PCR positive specimens; however, they did not correlate these results
198 with viral load titres.^{9,59,60}

199 Only one study reported the duration of viable virus shedding in respiratory samples; the median
200 time to clearance from URT and LRT samples was 3.5 and 6 days, respectively.²⁰ Arons *et al.*
201 cultured viable virus in one out of three asymptomatic cases from the respiratory tract.⁵⁴

202 Viral culture was successful in two of three RNA-positive patients in one study, but the time
203 points from symptom onset were not reported.⁶¹ Andersson *et al.* failed to culture virus from 27
204 RT-PCR positive serum samples.⁶²

205 **Summary of SARS-CoV-1 and MERS studies**

206 Eight studies on SARS-CoV-1 were included; the majority of studies did not report mean or median
207 duration of viral shedding thus, were not eligible for quantitative analysis. The maximum duration
208 of viral shedding reported was 8 weeks in URT,^{63,64} 52 days in LRT,^{63,65} 6-7 weeks in serum,⁶⁶
209 and 126 days in stool samples.^{63,65,67-69} Dialysis patients had longer viral shedding in stool
210 compared to non-dialysis patients.⁶⁸ Studies that have evaluated SARS-CoV-1 kinetics found low
211 viral load in the initial days of illness, increasing after the first week of illness in URT samples,
212 peaking at day 10,⁷⁰ or day 12-14,⁶⁷ and declining after week 3-4.⁶⁴ High viral loads correlated with
213 severity of illness⁶⁴ and poor survival.⁶⁴ While Chen *et al.* identified an association between

214 younger age and lower viral titers, ⁶⁴ Leong *et al.* found no difference.⁶⁹ Viable SARS-CoV-1 was
215 isolated from stool and respiratory samples up to 4 weeks, and urine specimens up to day 36.^{63,66}
216 All attempts to isolate virus from RT-PCR–positive stool specimens collected >6weeks after
217 disease onset failed.⁶⁵ The isolation probability for stool samples was approximately 5 to 10
218 times lower compared to respiratory specimens.⁶³

219 We identified 11 studies on MERS-CoV. Three studies (324 subjects) reporting MERS-CoV
220 shedding in URT and four studies (93 subjects) in LRT were included in the quantitative analysis.
221 The mean shedding duration was 15.3 days (95% CI, 11.6 – 19.0) and 16.6 days (95% CI, 14.8 –
222 18.4), respectively (Supplementary Figures 1 and 2). Only one study reported duration of viral
223 shedding in serum with a median of 14 days and max of 38 days.⁷¹ In a small study, mortality rates
224 were higher in patients with viraemia.⁷² In URT and LRT specimens, prolonged shedding was
225 associated with illness severity^{73,74} and survival⁷⁵ with the shortest duration observed in
226 asymptomatic patients.⁷³ Peak viral loads were observed between days 7 to 10 and higher viral
227 loads was observed among patients with severe illness and fatal outcome.^{71,73,74,76,77} Differences
228 in viral loads between survivors and fatal cases was more pronounced in the second week of
229 illness ($P < 0.0006$).⁷⁷ The proportion of successful viable culture was 6% in respiratory samples
230 with a viral load values below 10^7 copies/ml.⁷⁸

231 **Qualitative analysis**

232 All but 11 studies (6 cohort studies, 2 cross-sectional studies, and 1 RCT on SARS-CoV-2 and 2
233 cohort studies on MERS-CoV) were case series, the majority of which recruited non-consecutive
234 patients and therefore prone to possible selection bias. (Supplementary Table 1)

235 **DISCUSSION**

236 This systematic review and meta-analysis provide comprehensive data on the viral dynamics of
237 SARS-CoV-2 including the duration of RNA shedding and viable virus isolation. Our findings
238 suggest that while patients with SARS-CoV-2 infection may have prolonged RNA shedding,
239 median time to live virus clearance from upper and lower respiratory tract samples were 3.5 days
240 and 6 days, respectively. No live virus isolated from culture beyond day nine of symptoms

241 despite persistently high viral RNA loads, thus emphasizing that the infectious period cannot be
242 inferred from the duration of viral RNA detection. This finding is supported by several studies
243 demonstrating a relationship between viral load and viability of virus, with no successful culture
244 from samples below a certain viral load threshold.

245 SARS-CoV-2 viral load appears to peak in the URT within the first week of illness, and later in
246 the LRT. In contrast, peaks in SARS-CoV-1 and MERS-CoV viral loads in the URT occurred at
247 days 10-14 and 7-10 days of illness, respectively. Combined with isolation of viable virus in
248 respiratory samples primarily within the first week of illness, patients with SARS-CoV-2 infection
249 are likely to be most infectious in the first week of illness. Several studies report viral load peaks
250 during the prodromal phase of illness or at the time of symptom onset,^{2,4,8,16-23} providing a
251 rationale for the efficient spread of SARS-CoV-2. This is supported by the observation in contact
252 tracing studies that the highest risk of transmission occurs during the prodromal phase or early in
253 the disease course.^{79,80} No secondary cases were identified beyond 5 days after the symptom
254 onset.⁸¹ Although modelling studies estimated potential viral load peak before symptom onset,
255 we did not identify any study that confirms pre-symptomatic viral load peak.¹⁶

256 Emerging evidence suggests a correlation between virus persistence and disease severity and
257 outcome.^{18,25,27-29,38} This is consistent with the viral load dynamics of influenza, MERS-CoV, and
258 SARS-CoV-1 whereby severe disease was also associated with prolonged viral shedding.^{73,74,82}
259 However, more studies are needed to understand the duration of viable virus in patients with
260 severe illness.

261 Similar to SARS-CoV-1, SARS-CoV-2 can be detected in stool for prolonged periods, with high
262 viral loads detected even after 3 weeks of illness. A clear difference between SARS-CoV-1 and
263 MERS-CoV is the detection of viral RNA in stool. In SARS-CoV-1, RNA prevalence in stool
264 samples was high, with almost all studies reporting shedding in stool. Although viable SARS-
265 CoV-1 was isolated up to 4 weeks of illness, fecal-oral transmission was not considered to be a
266 primary driver of infection. Whereas in MERS-CoV, none of the studies reported duration of viral
267 shedding in stool and RNA detection was low.^{77,83} To date, only a few studies have

268 demonstrated viable SARS-CoV-2 in stool.^{61,84} Thus, the role of fecal shedding in viral
269 transmission remains unclear.

270 Viral loads at the start of infection appear to be comparable between asymptomatic and
271 symptomatic patients infected with SARS-CoV-2. Nevertheless, most studies demonstrate faster
272 viral clearance among asymptomatic individuals. This suggests similar transmission potential
273 among both groups at the onset of infection, but a shorter period of infectiousness in
274 asymptomatic patients. This is in keeping with viral kinetics observed with other respiratory
275 viruses such as influenza and MERS-CoV, in which people with asymptomatic infection have a
276 shorter duration of viral shedding than symptomatic individuals.^{73,85} However, there are limited
277 data on the shedding of infectious virus in asymptomatic individuals to quantify their transmission
278 potential to inform policy on quarantine duration in the absence of testing.

279 This is the first study that has comprehensively examined and compared SARS-CoV-2, SARS-
280 CoV-1 and MERS-CoV viral dynamics and performed a meta-analysis of viral shedding duration.
281 Our study has limitations. First, some patients in the included studies received a range of
282 treatments, including steroids and antivirals, which may have modified the shedding dynamics.
283 Second, most of the included studies are case series, which are particularly vulnerable to
284 selection bias. Third, our meta-analysis identified substantial study heterogeneity, likely due to
285 differences in study population, follow up and management approaches. Further, shedding
286 duration is reported as median \pm IQR for most studies, but meta-analysis necessitates
287 conversion to mean \pm SD.⁶ The validity of this conversion is based on the assumption that
288 duration of viral shedding is normally distributed, which may not apply to some studies. Lastly,
289 although there is likely a broad overlap, the true clinical window of infectious shedding may not
290 entirely align with viral culture duration.

291 We identified a systematic review of SARS CoV-2 viral load kinetics that included studies
292 published up until 12 May 2020.⁸⁶ This review included many studies that did not meet our
293 eligibility criteria, including 26 case reports and 13 case series involving <5 individuals; these are
294 prone to significant selection bias, reporting atypical cases with prolonged viral shedding.
295 Additionally, the review included studies that reported viral shedding duration from the time of

296 hospital admission or initial PCR positivity, rather than symptom onset. Furthermore, no meta-
297 analysis of the duration of viral shedding was performed.

298 This review provides detailed understanding about the available evidence to date on viral
299 dynamics of SARS-CoV-2 and has implications for pandemic control strategies and infection
300 control practices. Although SARS-CoV-2 RNA shedding can be prolonged in respiratory and
301 stool samples, the duration of viable virus is short-lived, with culture success associated with
302 viral load levels. No study has reported live SARS-CoV-2 beyond day nine to date. Most studies
303 detected the SARS-CoV-2 viral load peak within the first week of illness. These findings highlight
304 that isolation practices should be commenced with the start of first symptoms including mild and
305 atypical symptoms that precede more typical COVID-19 symptoms. This systematic review
306 underscores the importance of early case finding and isolation, as well as public education on
307 the spectrum of illness. However, given potential delays in the isolation of patients, effective
308 containment of SARS-CoV-2 may be challenging even with an early detection and isolation
309 strategy.⁸⁷

310

311 **Authors contributions:**

312 M. Cevik: conceptualisation, methodology, investigation, data curation, writing – original draft. M.
313 Tate: investigation, data curation, writing – original draft; O Lloyd: investigation, data curation,
314 writing – review and editing; A. E. Maraolo: formal analysis, writing – original draft; J. Schafers:
315 investigation, data curation, writing – review and editing; A Ho: conceptualisation, methodology,
316 data curation, writing – original draft, supervision.

317

318 **Financial support and sponsorship**

319 No financial support received

320 **Conflicts of interest**

321 All authors have nothing to disclose.

322 **Acknowledgements**

323 We would like to thank Vicki Cormie at the University of St Andrews for assistance with the
324 search and obtaining papers not readily accessible.

Table 1: Summary of included studies

| Study | Geographical location | Study setting | Study design | Number of patients | Age Median (IQR) | Male sex N (%) | Specimen types |
|--------------------------------|---------------------------------|---------------|-----------------|--------------------|------------------|----------------|-------------------------------------|
| SARS-CoV-2 | | | | | | | |
| Andersson et al. ⁶² | Oxford, UK | Hospital | Case series | 167 | 56 (46-76) | 89 (53) | Serum |
| Arons et al. ⁵⁴ | King's County, USA | Care home | Cross-sectional | 46 | 78.6 ± 9.5* | NR | URT |
| Bullard et al. ⁵⁷ | Manitoba, Canada | Hospital | Case series | 90 | 45 (30-59) | 44 (49) | Respiratory samples (not specified) |
| Cai et al. ⁷ | Shanghai/ Hefei/ Qingdao, China | Hospital | Case series | 10 | 6 | 4 (40) | LRT, blood, stool, urine |
| Cai et al. ²⁶ | Shenzhen, China | Hospital | Case series | 298 | 47 (33-61) | 149 (50) | URT |
| Chang et al. ⁸⁸ | Beijing, China | Hospital | Case series | 16 | 35.5 (24-53) | 11 (69) | URT |
| Chau et al. ⁵³ | Ho Chi Minh City, Vietnam | Hospital | Case series | 30 | 29 (16-60) | 15 (50) | URT |
| Chen et al. ²⁷ | Shanghai, China | Hospital | Case series | 249 | 51 (36-64) | 126 (51) | URT |
| Chen et al. ⁸⁹ | Wuhan, China | Hospital | Case series | 25 | 51.4 ±16.6* | 11 (44) | URT |
| Chen et al. ²⁸ | Guangzhou, China | Hospital | Case series | 284 | 48 (33-62) | 131 (46) | URT |
| Chen et al. ²⁹ | Wuhan, China | Hospital | Case series | 42 | 51 | 15 (36) | URT, stool, urine |
| Corman et al. ⁹⁰ | Germany | Hospital | Case series | 18 | NR | 12 (67) | Blood |
| Fan et al. ³⁰ | Shenyang, China | Hospital | Case series | 55 | 46.8 | 30 (55) | URT, sputum |
| Fang et al. ³¹ | Xiangtan, China | Hospital | Case series | 32 | 41 | 16 (50) | URT, stool, blood |
| Fu et al. ⁹¹ | Huazhong, China | Hospital | Case series | 50 | 64 (37-87) | 27 (54) | URT |
| Han et al. ⁸ | Chongqing, South Korea | Hospital | Case series | 12 | 6.5 (0.007-16) | 5 (42) | URT, stool |
| He et al. ¹⁶ | Guangzhou, China | Hospital | Case series | 94 | 46 | 47 (50) | URT |
| Hu et al. ³⁷ | Qingdao, China | Hospital | Case series | 59 | 46 (33-57) | 28 (47) | URT |
| Hu et al. ⁵⁵ | Nanjing, China | Hospital | Case series | 24 | 32.5 (21-57) | 8 (33) | URT |
| Huang et al. ⁵¹ | Guangzhou, China | Hospital | Case series | 27 | NR | 12 (44) | URT |

| | | | | | | | |
|---------------------------------------|--|-------------------------|----------------------|---------------------------|----------------------|----------|---|
| Huang et al. ²³ | Wenzhou, China | Hospital | Case series | 33 | 47 (range 2-84) | 17 (52) | URT, LRT, stool |
| Huang et al. ⁹² | Wuhan, China | Hospital | Retrospective cohort | 200 | 58± 17* | 115 (48) | URT |
| Hung et al. ⁵⁰ | Hong Kong | Hospital | RCT | 127 | 52 (32-62) | 68 (54) | URT, stool |
| Kim et al. ⁴ | Soeul/ Incheon/ Seongna, South Korea | Hospital | Case series | 28 | 40 (28-54) | 15 (54) | URT, LRT |
| Kujawski et al. ¹⁷ | 6 states, USA | Hospital /Outpatient | Case series | 12 | 53 (range 21- 68) | 8 (75) | URT, LRT, stool, blood, urine |
| L'Huillier et al. ⁹ | Geneva, Switzerland | Hospital | Case series | 23 | 12 (3.8-14.5) | NR | URT |
| La Scola et al. ⁵⁸ | France | Hospital | Case series | 155 | NR | NR | URT, LRT |
| Lavezzo et al. ¹⁴ | Vo', Italy | Community | Cross-sectional | Only sample # reported | Mixed | Mixed | URT |
| Le et al. ⁵⁹ | Hanoi, Vietnam | Hospital | Case series | 12 | 29.5* | 3 (25) | URT |
| Li et al. ⁹³ | Wuhan China | Hospital | Case series | 36 | 57.5 (52-65) | 23 (64) | URT |
| Liang et al. ⁴⁹ | Wuhan, China | Hospital | Case series | 120 | 61.5 (47-70) | 68 (57) | URT |
| Ling et al. ⁴⁷ | Shanghai, China | Hospital | Case series | 66 | 44 (16-778) | 38 (58) | URT, stool, blood, urine |
| Liu et al. ⁹⁴ | Wuhan, China | Hospital | Case series | 238 | 55 (38.3-65) | 138 (58) | URT |
| Liu et al. ³² | Nanchang, China | Hospital | Case series | 76 | 48.3 | 48 (63) | URT |
| Lo et al. ⁹⁵ | Macau, China | Hospital | Case series | 10 | 54 (27-64) | 3 (30) | URT, LRT, stool, urine |
| Lou B et al. ⁹⁶ | Zhejiang, China | Hospital | Case series | 80 | 55 (45-64) | 50 (69) | LRT |
| Pongpirul et al. ⁹⁷ | Bangkok, Thailand | Hospital | Case series | 11 | 61 (28-74) | 6 (55) | URT |
| Qian et al. ⁹⁸ | Ningbo, China | Hospital | Case series | 24 | NR | NR | URT |
| Quan et al. ⁹⁹ | Wuhan/Shenzhen/ Xiangyang, China | Hospital | Case series | 23 | 60.3 ±15.3* | 23 (100) | Prostatic secretions all negative (URT) |

| | | | | | | | |
|-------------------------------------|-------------------|---------------------|--------------------|-----|--|----------|--|
| Sakurai et al. ⁴³ | Aichi, Japan | Hospital | Case series | 90 | 59.5 (36-68) | 53 (59) | URT |
| Seah et al. ¹⁰⁰ | Singapore | Hospital | Case series | 17 | NR | NR | Tears |
| Shastri et al. ⁴⁶ | Mumbai, India | Reference lab | Case series | 68 | 37 (range 3-75) | 48 (71) | URT |
| Shi et al. ³³ | Wuhan, China | Hospital | Case series | 246 | 58 (47-67) | 126 (51) | URT |
| Song et al. ¹⁰¹ | Nanjing, China | Hospital | Case series | 13 | 22 – 67 (range only) | 13 (100) | URT, semen, testicular sample |
| Song et al. ¹⁰² | Beijing, China | Hospital/Outpatient | Case series | 21 | 37 (21-59.5) | 8 (38) | URT |
| Talmy et al. ⁴⁴ | Ramat Gan, Israel | Outpatient | Case series | 119 | 21 (19-25) | 84 (71) | URT |
| Tan et al. ³⁴ | Chongqing, China | Hospital | Case series | 142 | NR | NR | URT |
| Tan et al. ¹⁸ | Chongqing, China | Hospital | Case series | 67 | 49 (10-77) | 35 (52) | URT, LRT, stool, blood, urine |
| Tan et al. ¹⁰ | Changsha, China | Hospital | Case series | 10 | 7 (1-12) | 3 (30) | URT, stool |
| Tian et al. ⁴¹ | Beijing, China | Hospital/Outpatient | Case series | 75 | 41.5 (range 0.8 – 88)* | 42 (56) | Respiratory tract sample (not specified further) |
| To et al. ¹⁹ | Hong Kong, China | Hospital | Case series | 23 | 62 (37-75) | 13 (57) | URT, stool, blood, urine |
| To et al. ⁶⁰ | Hong Kong, China | Hospital | Prospective Cohort | 12 | 62.5 (37-75) | 7 (58) | URT (saliva) |
| Tu et al. ¹⁰³ | Anhui, China | Hospital | Case series | 40 | Viral shedding <10 days: 40.86 ± 8.26 Viral shedding ≥10 days: 45.5 ± 14.60 | 21 (53) | URT |
| Wang et al. ¹⁰⁴ | Henan, China | Hospital | Case series | 18 | 39 (29-55) | 10 (56) | URT |
| Wang et al. ¹⁰⁵ | Jinhua, China | Hospital | Case series | 17 | 42 ± 17* | 10 (59) | URT, stool |
| Wölfel et al. ²⁰ | Munich, Germany | Hospital | Case series | 9 | NR | NR | URT, blood, urine |
| Wu et al. ¹⁰⁶ | Hainan, China | Hospital | Case series | 91 | 50 (range 21-83)* | 52 (57) | URT, stool |

| | | | | | | | |
|--------------------------------------|------------------------------|----------|----------------------|---------------------|---|---|------------------------------|
| Wu et al. ¹¹ | Qingdao, China | Hospital | Case series | 74 | 6 (0.1-15.08 range) | 44 (59) | Stool |
| Wu et al. ⁴⁰ | Zhuhai, China | Hospital | Case series | 74 | 43.8* | 35 (47) | Stool |
| Wyllie et al. ²¹ | New Haven, USA | Hospital | Case series | 44 | 61 (23-92 range)* | 23 (52) | URT (saliva) |
| Xiao et al. ⁴⁵ | Wuhan, China | Hospital | Case series | 56 | 55 (42-68) | 34 (61) | URT |
| Xiao et al. ⁶¹ | Guangzhou, China | Hospital | Case series | 28 | | | Stool |
| Xu et al. ³⁸ | Shenzhen/ Zhejiang, China | Hospital | Retrospective Cohort | 113 | 52 (42-63) | 66 (58) | URT |
| Xu et al. ¹⁰⁷ | Shenyang, China | Hospital | Case series | 14 | 48 ± 13.4* | 7 (50) | URT, LRT, serum, conjunctiva |
| Xu et al. ¹² | Guangzhou, China | Hospital | Case series | 10 | 6.6 | 6 (60) | URT, rectal swab |
| Yan et al. ³⁹ | Hubei, China | Hospital | Case series | 120 | 52 (35-63) | 54 (45) | URT |
| Yang et al. ⁵⁶ | Wuhan, China | Hospital | Case series | 78 (45 symptomatic) | Symptomatic: 56 (34-63) Asymptomatic: 37 (26-45) | Symptomatic: 31 (40) Asymptomatic: 11 (33) | URT |
| Yang et al. ¹⁰⁸ | Shenzhen, China | Hospital | Case series | 213 | 52 (range 2-86) | 108 (51) | URT, LRT |
| Yongchen et al. ³⁶ | Nanjing, Xuzhou, China | Hospital | Case series | 21 | 37 | 13 (62) | URT, stool |
| Young et al. ²² | Singapore | Hospital | Case series | 18 | 47 | 9 (50) | URT, stool, blood, urine |
| Zha et al. ⁴⁸ | Wuhu, China | Hospital | Case series | 31 | 39 (32-54) | 20 (65) | URT |
| Zhang et al. ²⁴ | Beijing, China | Hospital | Case series | 23 | 48 (40-62) | 12 (52) | URT, stool, blood, urine |
| Zhang et al. ¹³ | Shenzhen, China | Hospital | Case series | 56 | Mixed | Mixed | URT, stool |
| Zheng et al. ²⁵ | Zhejiang, China | Hospital | Retrospective Cohort | 96 | 53 (33.4-64.8) | NR | LRT, stool, blood, urine |
| Zhou et al. ⁴² | Wuhan, China | Hospital | Case series | 41 | 58 (48-62) | 22 (54) | URT |
| Zhou et al. ³⁵ | Wuhan, China | Hospital | Case series | 191 | 56 (46-67) | 119 (62) | URT |
| Zhou et al. ⁵² | Guangzhou, China | Hospital | Case series | 31 | 45 (33-60) 37 (28-57) | 4 (44) 6 (27) | URT |
| Zhu et al. ¹⁵ | Wuhan, China | Hospital | Case series | 10 | 49.5 | 8 (80) | URT |

| | | | | | | | |
|---------------------------------------|---------------------------|---------------------|-------------|----------------------------|--|----------|-------------------------------|
| Zou et al.² | Zhuhai, China | Hospital/outpatient | Case series | 18 | 59 (range 26-76) | 9 (50) | URT |
| SARS-CoV-1 | | | | | | | |
| Chan et al.⁶³ | Hong Kong, China | Hospital | Case series | 415 | 11.3 ± 4.1* 37.1 ± 11.2* | 132 (33) | URT, LRT, stool, urine |
| Chen et al.⁶⁴ | Taiwan | Hospital | Case series | 108 | Stratified | 95 | URT |
| Cheng et al.⁶⁷ | Hong Kong, China | Hospital | Case series | 1041 | NR | NR | URT, LRT, stool, urine |
| Kwan et al.⁶⁸ | Hong Kong, China | Hospital | Case series | 12 dialysis 33 controls | Dialysis: 58 (range 34-74);* Controls: 57 (range 34-75) | 6 (50) | URT, stools, urine |
| Liu et al.⁶⁵ | Beijing, China | Hospital | Case series | 56 | 31 (male) 34 (female) | 31 (55) | LRT, stool |
| Leong et al.⁶⁹ | Singapore | Hospital | Case series | 64 | 35.2 (17-63 range)* | 16 (25) | URT, stool, blood, urine |
| Peiris et al.⁷⁰ | Hong Kong, China | Hospital | Case series | 75 | 39.8 (SD 12.2) | 0.92 | URT |
| Xu et al.¹⁰⁹ | Beijing, China | Hospital | Case series | 54 | NR | NR | LRT, blood, urine |
| MERS-CoV | | | | | | | |
| Al Hosani et al.⁷³ | Abu Dhabi, UAE | Hospital/community | Case series | 65 | 20 -59 | 43 (66) | LRT |
| Al-Jasser et al.¹¹⁰ | Riyadh, Saudi Arabia | Hospital | Case series | 167 | 46.71* | 142 (57) | URT |
| Alkendi et al.¹¹¹ | Tawam/Al Ain, UAE | Hospital | Case series | 58 | 43.5 | 41 (71) | URT |
| Arabi et al.⁷⁵ | Saudi Arabia | Hospital | Cohort | 330 | 58 (44-69) | 225 (68) | URT |
| Corman et al.⁷⁷ | Riyadh, Saudi Arabia | Hospital | Case series | 37 | 69 (24-90)* | 27 (39) | URT, LRT, stool, blood, urine |
| Hong et al.⁷⁶ | Seoul, South Korea | Hospital | Case series | 30 | 49* | 19 (63) | Blood |
| Min et al.⁷¹ | Seoul/others, South Korea | Hospital | Case series | 14 | 62 | 6 (35) | LRT, serum |
| Muth et al.⁷⁸ | Riyadh, Saudi Arabia | Hospital | Case series | 32 | 66 (24-90) | 24 (75) | LRT |
| Oh et al.⁷⁴ | Seoul, South Korea | Hospital | Case series | 17 | NR | NR | URT, LRT, serum |
| Park et al.¹¹² | Seoul, South Korea | Hospital | Case series | 17 | NR | NR | URT, LRT |

| | | | | | | | |
|-------------------------------------|----------------------|----------|----------------------|----|----|---------|------------|
| Shalhoub et al.⁷² | Jeddah, Saudi Arabia | Hospital | Retrospective cohort | 32 | 65 | 14 (44) | LRT, serum |
|-------------------------------------|----------------------|----------|----------------------|----|----|---------|------------|

327 Abbreviations: UK, United Kingdom, USA; United States of America; UAE, United Arab Emirates; RCT, randomised controlled trial; URT, upper respiratory
328 tract; LRT, lower respiratory tract; NR, not reported.

329 * Mean ± standard deviation (or range if stated).

330

331

332

333

334

335

336

337

338

339

340

341

342

343 **Table 2: Severity of illness and viral dynamics**

| Study | Classification of severity | Median duration - days (IQR) | Viral dynamics in severe patients compared to non-severe patients | P-value |
|----------------------------------|-----------------------------------|-------------------------------------|--|----------------------|
| Chen et al.²⁷ | ICU vs. non-ICU patients | 11 | Median time to viral clearance significantly longer in ICU vs. non-ICU patients (HR=3.17, 95% CI, 2.29-4.37) | Only HR provided |
| Chen et al.²⁸ | China CDC guideline (version 7) | 12 (8-16) | Shedding duration varies by severity: asymptomatic 6 days; mild 10 days; moderate 12 days; serious 14 days; critical 32 days | <0.0001 |
| Tan et al.¹⁸ | China CDC guideline (version 6) | NP: 12 Any sample: 22 | Viral shedding significantly longer in severe patients: any sample 23 vs. 20 days (note NP: 14 vs. 11 days – non-significant) | p=0.023 (any sample) |
| Xu et al.³⁸ | WHO criteria | 17 (13-32) | Higher proportion of severe patients had shedding >21 days (34.2% vs. 16.2%) | 0.49 |
| Yan et al.³⁹ | China CDC guideline (version 6) | 23 (18-32) | No difference in shedding duration (general 23 days vs. severe 26 days vs. critical 28 days) | 0.51 |
| Zheng et al.²⁵ | China CDC guideline (version 6) | Resp: 18 (13-29) | Shedding duration significantly longer in severe patients (21 vs 14 days) in respiratory samples. No difference in shedding duration in stool/serum | p=0.04 |

344 Abbreviations: IQR, interquartile range; ICU, intensive care unit; HR, hazard ratio; CDC, Centers
 345 for Disease Control and Prevention; WHO, World Health Organization.

346

347

348

349

350

351


352

353 **Table 3: SARS-CoV-2 viral dynamics in asymptomatic patients compared to symptomatic**
 354 **patients**

| | Median duration – days (IQR) | Viral dynamics in asymptomatic patients compared to symptomatic patients | P-value |
|--|-------------------------------------|--|----------------|
| Arons <i>et al.</i>⁵⁴ | NR | No difference in viral load | NS |
| Chau <i>et al.</i>⁵³ | NR | Initial viral load similar. Asymptomatic patients had significantly lower viral load during the follow up compared to symptomatic patients and faster viral clearance in asymptomatic, compared to symptomatic individuals | 0.027 |
| Chen <i>et al.</i>²⁸ | 6 (3.5-10) | Significantly shorter duration of viral shedding among asymptomatic cases (median 6 days, IQR 3.5-10), with increasing shedding duration associated with increasing illness severity | <0.0001 |
| Han <i>et al.</i>⁸ | NR | Symptomatic children had higher initial RNA load in nasopharyngeal swab specimens than asymptomatic children (9.01 vs. 6.32 log ₁₀ copies/mL; p = 0.048). | 0.048 |
| Hu <i>et al.</i>⁵⁵ | 6 (2-12) | Asymptomatic patients had shorter duration of viral shedding compared to pre-symptomatic patients (median duration of SARS-CoV-2 positivity was 6.0 (2.0 - 12.0) compared to 12.0 (12.0 - 14.0)) | NR |
| Lavezzo <i>et al.</i>¹⁴ | NR | No difference in viral load | NS |
| Le <i>et al.</i>⁵⁹ | 9 | NR | N/A |
| Sakurai <i>et al.</i>⁴³ | 9 (6-11) | NR | N/A |
| Yang <i>et al.</i>⁵⁶ | 8 (3-12) | Significantly shorter duration of viral shedding from nasopharynx swabs was observed among asymptomatic compared to symptomatic patients | P= .001 |
| Yongchen <i>et al.</i>³⁶ | 18 (5-28) | Longer shedding duration among asymptomatic cases (median 18 days, range 5-28), compared to non-severe (10 days, range 2-21) and severe (14 days, range 9-33) cases | NS |
| Zhang <i>et al.</i>¹³ | 9.63 | Initial viral load similar, viral clearance occurred earlier in the asymptomatic (9.6 days) and symptomatic individuals (9.7 days, compared to pre-symptomatic group (13.6 days) | |
| Zhou <i>et al.</i>⁵² | NR | Significantly higher viral load in symptomatic (n=22) compared to asymptomatic (n=9) patients (median cycle threshold (Ct) value 34.5 vs. 39.0, respectively) but duration of shedding was similar | |

355 Abbreviations: IQR, interquartile range; RNA, ribonucleic acid; NR, not reported; NS, non-
 356 significant; N/A, not applicable


Figure 1. Flowchart describing study selection



From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097

For more information, visit www.prisma-statement.org.


Figure 2: Pooled mean duration (days) of SARS-CoV-2 shedding from the upper respiratory tract (random-effects model).



Note: the overall effect is plotted as a black square.

Test for heterogeneity: Q-value = 4076,08, df(Q) = 42, $p < 0.001$, $I^2 = 99\%$.


Figure 3: Pooled mean duration (days) of SARS-CoV-2 shedding from the lower respiratory tract (random-effects model).



Note: the overall effect is plotted as a black square.

Test for heterogeneity: Q-value = 203.3, df(Q) = 6, $p < 0.001$, $I^2 = 97\%$.


Figure 4. Pooled mean duration (days) of SARS-CoV-2 shedding in the blood (random-effects model).



Note: the overall effect is plotted as a black square.

Test for heterogeneity: Q-value = 77.6, df(Q) = 1, $p < 0.001$, $I^2 = 99\%$.


Figure 5. Pooled mean duration (days) of SARS-CoV-2 shedding from the stool (random-effects model).



Note: the overall effect is plotted as a black square.

Test for heterogeneity: Q-value = 356.0, df(Q) = 12, p < 0.001, I² = 96.6%.

Figure 6. Meta-regression bubble plot of the impact of age on mean SARS-CoV-2 shedding from the upper respiratory tract



URT: upper respiratory tract.

Note: the plot was built upon 41 studies (no data on mean age from the study of Qian et al.⁹⁸). A random-effects model was used.

References:

1. Cevik M, Bamford CGG, Ho A. COVID-19 pandemic-a focused review for clinicians. *Clin Microbiol Infect* 2020; **26**(7): 842-7.
2. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* 2020; **382**(12): 1177-9.
3. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020.
4. Kim ES, Chin BS, Kang CK, et al. Clinical Course and Outcomes of Patients with Severe Acute Respiratory Syndrome Coronavirus 2 Infection: a Preliminary Report of the First 28 Patients from the Korean Cohort Study on COVID-19. *J Korean Med Sci* 2020; **35**(13): e142.
5. Institute TJB. The Joanna Briggs Institute Critical Appraisal tools for use in JBI systematic reviews—checklist for case series. , 2017.
6. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. *BMC Medical Research Methodology* 2014; **14**(1): 135.
7. Cai J, Xu J, Lin D, et al. A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features. *Clinical Infectious Diseases* 2020; **28**: 28.
8. Han MS, Seong M-W, Kim N, et al. Early Release - Viral RNA Load in Mildly Symptomatic and Asymptomatic Children with COVID-19, Seoul - Volume 26, Number 10—October 2020 - Emerging Infectious Diseases journal - CDC.
9. L'Huillier A, Torriani G, Pigny F, Kaiser L, Eckerle I. Shedding of infectious SARS-CoV-2 in symptomatic neonates, children and adolescents. 2020.
10. Tan Y-p, Tan B-y, Pan J, Wu J, Zeng S-z, Wei H-y. Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019 in Changsha, China. *Journal of Clinical Virology* 2020; **127**: 104353.
11. Wu Q, Xing Y, Shi L, et al. Epidemiological and Clinical Characteristics of Children with Coronavirus Disease 2019. 2020.
12. Xu Y, Li X, Zhu B, et al. Characteristics of pediatric SARS-CoV-2 infection and potential evidence for persistent fecal viral shedding. *Nature Medicine* 2020; **26**(4): 502-5.
13. Zhang Z, Xiao T, Wang Y, et al. Early viral clearance and antibody kinetics of COVID-19 among asymptomatic carriers. *medRxiv* 2020: 2020.04.28.20083139.
14. Lavezzo E, Franchin E, Ciavarella C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* 2020: 1-.
15. Zhu L, Gong N, Liu B, et al. Coronavirus Disease 2019 Pneumonia in Immunosuppressed Renal Transplant Recipients: A Summary of 10 Confirmed Cases in Wuhan, China. *Eur Urol* 2020; **18**: 18.
16. He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine*; **26**(5): 672-5.
17. Kujawski SA, Wong KK, Collins JP, et al. Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. *Nature Medicine* 2020; **26**(6): 861-8.
18. Tan W, Lu Y, Zhang J, et al. Viral Kinetics and Antibody Responses in Patients with COVID-19. 2020.
19. To KK-W, Tsang OT-Y, Leung W-S, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases* 2020; **20**(5): 565-74.
20. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020; **581**(7809): 465-9.
21. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs.

22. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. *JAMA* 2020; **03**: 03.
23. Huang J, Mao T, Li S, et al. Long period dynamics of viral load and antibodies for SARS-CoV-2 infection: an observational cohort study. *medRxiv* 2020: 2020.04.22.20071258.
24. Zhang N, Gong Y, Meng F, Bi Y, Yang P, Wang F. Virus shedding patterns in nasopharyngeal and fecal specimens of COVID-19 patients. 2020.
25. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* 2020; **369**.
26. Cai Q, Huang D, Ou P, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. *Allergy* 2020; **n/a**(n/a).
27. Chen J, Qi T, Liu L, et al. Clinical progression of patients with COVID-19 in Shanghai, China. *Journal of Infection* 2020; **80**(5): e1-e6.
28. Chen X, Zhang Y, Zhu B, et al. Associations of clinical characteristics and antiviral drugs with viral RNA clearance in patients with COVID-19 in Guangzhou, China: a retrospective cohort study.
29. Chen Y, Chen L, Deng Q, et al. The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients. *Journal of Medical Virology* 2020; **03**: 03.
30. Fan L, Liu C, Li N, et al. Medical treatment of 55 patients with COVID-19 from seven cities in northeast China who fully recovered: a single-center, retrospective, observational study.
31. Fang Z, Zhang Y, Hang C, Ai J, Li S, Zhang W. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients. *Journal of Infection* 2020; **21**: 21.
32. Liu Y, Yan L-M, Wan L, et al. Viral dynamics in mild and severe cases of COVID-19. *Lancet Infect Dis* 2020; **20**(6): 656-7.
33. Shi J, Cheng C, Yu M, et al. Systemic Inflammatory Cytokines Associate With SARS-COV-2 Viral Shedding Time in Covid-19 Inpatients. *ResearchSquare* 2020.
34. Tan L, Kang X, Ji X, et al. Validation of Predictors of Disease Severity and Outcomes in COVID-19 Patients: A Descriptive and Retrospective Study. *Med* 2020.
35. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-62.
36. Yongchen Z, Shen H, Wang X, et al. Different longitudinal patterns of nucleic acid and serology testing results based on disease severity of COVID-19 patients. *Emerg* 2020; **9**(1): 833-6.
37. Hu X, Xing Y, Jia J, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. *Science of the Total Environment* 2020; **728** (no pagination).
38. Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with COVID-19. *Clinical Infectious Diseases* 2020; **09**: 09.
39. Yan D, Liu X-y, Zhu Y-n, et al. Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection.
40. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. *Lancet Gastroenterol Hepatol* 2020; **5**(5): 434-5.
41. Tian D, Wang L, Wang X, et al. Clinical research and factors associated with prolonged duration of viral shedding in patients with COVID-19. *ResearchSquare* 2020.
42. Zhou B, She J, Wang Y, Ma X. The duration of viral shedding of discharged patients with severe COVID-19. *Clinical Infectious Diseases* 2020; **17**: 17.
43. Sakurai A, Sasaki T, Kato S, et al. Natural History of Asymptomatic SARS-CoV-2 Infection. *New England Journal of Medicine* 2020.
44. Talmy T, Tsur A, Shabtay O. Duration of Viral Clearance in IDF Soldiers with Mild COVID-19. *medRxiv*.
45. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: a preliminary study from 56 COVID-19 patients. *Clinical Infectious Diseases* 2020; **19**: 19.

46. Shastri A, Wheat J, Agrawal S, et al. Delayed clearance of SARS-CoV2 in male compared to female patients: High ACE2 expression in testes suggests possible existence of gender-specific viral reservoirs.
47. Ling Y, Xu S-B, Lin Y-X, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. *Chinese Medical Journal* 2020; **133**(9).
48. Zha L, Li S, Pan L, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). *Medical Journal of Australia* 2020; **212**(9): 416-20.
49. Liang M, Chen P, He M, et al. Corticosteroid Treatment in Critically Ill Patients with COVID-19: A Retrospective Cohort Study. *ResearchSquare* 2020.
50. Hung IFN, Lung KC, Tso EYK, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet* 2020; **395**(10238): 1695-704.
51. Huang H, Guan L, Yang Y, et al. Chloroquine, arbidol (umifenovir) or lopinavir/ritonavir as the antiviral monotherapy for COVID-19 patients: a retrospective cohort study. 2020.
52. Zhou R, Li F, Chen F, et al. Viral dynamics in asymptomatic patients with COVID-19. *International Journal of Infectious Diseases* 2020; **96**: 288-90.
53. Chau NVV, Thanh Lam V, Thanh Dung N, et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. *Clinical Infectious Diseases* 2020.
54. Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *New England Journal of Medicine* 2020; **382**(22): 2081-90.
55. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences* 2020; **63**(5): 706-11.
56. Yang R, Gui X, Xiong Y. Comparison of Clinical Characteristics of Patients with Asymptomatic vs Symptomatic Coronavirus Disease 2019 in Wuhan, China. *JAMA Netw Open* 2020; **3**(5).
57. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. *Clinical Infectious Diseases*.
58. La Scola B, Le Bideau M, Andreani J, et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. *Eur J Clin Microbiol Infect Dis* 2020: 1-3.
59. Le TQM, Takemura T, Moi ML, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Shedding by Travelers, Vietnam, 2020. *Emerg Infect Dis* 2020; **26**(7): 02.
60. To KK-W, Tsang OT-Y, Yip CC-Y, et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. *Clinical Infectious Diseases* 2020; (ciao149).
61. Xiao F, Sun J, Xu Y, et al. Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. *Emerging Infectious Disease journal* 2020; **26**(8).
62. Andersson M, Arancibia - Carcamo CV, Auckland K, et al. SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus. *medRxiv*.
63. Chan PK, To WK, Ng KC, et al. Laboratory diagnosis of SARS. *Emerg Infect Dis* 2004; **10**(5): 825-31.
64. Chen WJ, Yang JY, Lin JH, et al. Nasopharyngeal shedding of severe acute respiratory syndrome-associated coronavirus is associated with genetic polymorphisms. *Clinical Infectious Diseases* 2006; **42**(11): 1561-9.
65. Liu W, Tang F, Fontanet A, et al. Long-term SARS coronavirus excretion from patient cohort, China. *Emerg Infect Dis* 2004; **10**(10): 1841-3.
66. Xu D, Zhang Z, Jin L, et al. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. *European Journal of Clinical Microbiology and Infectious Diseases* 2005; **24**(3): 165-71.
67. Cheng PK, Wong DA, Tong LK, et al. Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome. *Lancet* 2004; **363**(9422): 1699-700.
68. Kwan BC, Leung CB, Szeto CC, et al. Severe acute respiratory syndrome in dialysis patients. *J Am Soc Nephrol* 2004; **15**(7): 1883-8.

69. Leong HN, Chan KP, Khan AS, et al. Virus-specific RNA and antibody from convalescent-phase SARS patients discharged from hospital. *Emerg Infect Dis* 2004; **10**(10): 1745-50.
70. Peiris JSM, Chu CM, Cheng VCC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. *The Lancet* 2003; **361**(9371): 1767-72.
71. Min CK, Cheon S, Ha NY, et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. *Sci* 2016; **6**: 25359.
72. Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. *J Antimicrob Chemother* 2015; **70**(7): 2129-32.
73. Al Hosani FI, Pringle K, Al Mulla M, et al. Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013-2014. *Emerg Infect Dis* 2016; **22**(7): 1162-8.
74. Oh MD, Park WB, Choe PG, et al. Viral load kinetics of MERS coronavirus infection. *New England Journal of Medicine* 2016; **375**(13): 1303-5.
75. Arabi YM, Al-Omari A, Mandourah Y, et al. Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. *Crit Care Med* 2017; **45**(10): 1683-95.
76. Hong KH, Choi JP, Hong SH, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). *Thorax* 2018; **73**(3): 286-9.
77. Corman VM, Albarak AM, Omrani AS, et al. Viral Shedding and Antibody Response in 37 Patients With Middle East Respiratory Syndrome Coronavirus Infection. *Clinical Infectious Diseases* 2016; **62**(4): 477-83.
78. Muth D, Corman VM, Meyer B, et al. Infectious middle east respiratory syndrome coronavirus excretion and serotype variability based on live virus isolates from patients in Saudi Arabia. *Journal of Clinical Microbiology* 2015; **53**(9): 2951-5.
79. Wang Y, Tian H, Zhang L, et al. Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Global Health* 2020; **5**(5): e002794.
80. Böhmer MM, Buchholz U, Corman VM, et al. Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *The Lancet Infectious Diseases*.
81. Cheng H-Y, Jian S-W, Liu D-P, et al. Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Internal Medicine* 2020.
82. Wang Y, Guo Q, Yan Z, et al. Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. *J Infect Dis* 2018; **217**(11): 1708-17.
83. Memish A. Viral shedding and antibody response in MERS. *Vox Sanguinis* 2016; **111** (Supplement 1): 48-9.
84. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* 2020; **323**(18): 1843-4.
85. Ip DKM, Lau LLH, Leung NHL, et al. Viral Shedding and Transmission Potential of Asymptomatic and Paucisymptomatic Influenza Virus Infections in the Community. *Clin Infect Dis* 2017; **64**(6): 736-42.
86. Walsh KA, Jordan K, Clyne B, et al. SARS-CoV-2 detection, viral load and infectivity over the course of an infection. *Journal of Infection*.
87. Kretzschmar ME, Rozhnova G, Bootsma MCJ, van Boven M, van de Wijgert JHHM, Bonten MJM. Impact of delays on effectiveness of contact tracing strategies for COVID-19: a modelling study. *The Lancet Public Health*.

88. Chang D, Mo G, Yuan X, et al. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. *Am J Respir Crit Care Med* 2020; **201**(9): 1150-2.
89. Chen X, Ling J, Mo P, et al. Restoration of leukomonocyte counts is associated with viral clearance in COVID-19 hospitalized patients. *medRxiv* 2020: 2020.03.03.20030437.
90. Corman VM, Rabenau HF, Adams O, et al. SARS-CoV-2 asymptomatic and symptomatic patients and risk for transfusion transmission. *Transfusion* 2020; **60**(6): 1119-22.
91. Fu S, Fu X, Song Y, et al. Virologic and clinical characteristics for prognosis of severe COVID-19: a retrospective observational study in Wuhan, China. 2020.
92. Huang L, Chen Z, Ni L, et al. Impact of Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Inflammatory Responses and Viral Clearance in COVID-19 Patients: A Multicenter Retrospective Cohort Study. *ResearchSquare* 2020.
93. Li N, Wang X, Lv T. Prolonged SARS-CoV-2 RNA shedding: Not a rare phenomenon. *Journal of Medical Virology*; **n/a**(n/a).
94. Liu L, Liu W, Zheng Y, et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients. *Microbes and Infection* 2020; **22**(4): 206-11.
95. Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. *Int J Biol Sci* 2020; **16**(10): 1698-707.
96. Lou B, Li T, Zheng S, et al. Serology characteristics of SARS-CoV-2 infection since the exposure and post symptoms onset.
97. Pongpirul WA, Mott JA, Woodring JV, et al. Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand - Volume 26, Number 7—July 2020 - Emerging Infectious Diseases journal - CDC.
98. Qian GQ, Chen XQ, Lv DF, et al. Duration of SARS-CoV-2 viral shedding during COVID-19 infection. *Infect Dis (Lond)* 2020: 1-2.
99. quan w, zheng q, tian j, et al. No SARS-CoV-2 in expressed prostatic secretion of patients with coronavirus disease 2019: a descriptive multicentre study in China.
100. Seah IYJ, Anderson DE, Kang AEZ, et al. Assessing Viral Shedding and Infectivity of Tears in Coronavirus Disease 2019 (COVID-19) Patients. *Ophthalmology* 2020; **24**: 24.
101. Song C, Wang Y, Li W, et al. Detection of 2019 novel coronavirus in semen and testicular biopsy specimen of COVID-19 patients.
102. Song R, Han B, Song M, et al. Clinical and epidemiological features of COVID-19 family clusters in Beijing, China. *Journal of Infection* 2020.
103. Tu Y-H, Wei Y-Y, Zhang D-W, Chen C-S, Hu X-W, Fei G. Analysis of factors affected the SARS-CoV-2 viral shedding time of COVID-19 patients in Anhui, China: a retrospective study. 2020.
104. Wang L, Gao Y-h, Lou L-L, Zhang G-J. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. *European Respiratory Journal* 2020.
105. Wang S, Tu J, Sheng Y. Clinical characteristics and fecal-oral transmission potential of patients with COVID-19. *medRxiv*.
106. Wu B, Lei Z-Y, Wu K-L, et al. Epidemiological and clinical features of imported and local patients with coronavirus disease 2019 (COVID-19) in Hainan, China. *ResearchSquare* 2020.
107. Xu I, Zhang X, Song W, et al. Conjunctival polymerase chain reaction-tests of 2019 novel coronavirus in patients in Shenyang, China.
108. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. 2020.
109. Xu D, Zhang Z, Jin L, et al. Persistent shedding of viable SARS-CoV in urine and stool of SARS patients during the convalescent phase. *Eur J Clin Microbiol Infect Dis* 2005; **24**(3): 165-71.
110. Al-Jasser FS, Nouh RM, Youssef RM. Epidemiology and predictors of survival of MERS-CoV infections in Riyadh region, 2014-2015. *J Infect Public Health* 2019; **12**(2): 171-7.

111. Alkendi F, Nair SC, Hashmey R. Descriptive Epidemiology, Clinical Characteristics and Outcomes for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Infected Patients in AlAin - Abu Dhabi Emirate. *J Infect Public Health* 2019; **12 (1)**: 137.
112. Park WB, Poon LLM, Choi SJ, et al. Replicative virus shedding in the respiratory tract of patients with Middle East respiratory syndrome coronavirus infection. *International Journal of Infectious Diseases* 2018; **72**: 8-10.